671,200 Shares in AngioDynamics, Inc. $ANGO Acquired by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY bought a new position in AngioDynamics, Inc. (NASDAQ:ANGO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 671,200 shares of the medical instruments supplier’s stock, valued at approximately $8,732,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its stake in shares of AngioDynamics by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock valued at $621,000 after acquiring an additional 1,076 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares in the last quarter. Deutsche Bank AG boosted its stake in AngioDynamics by 5.9% during the fourth quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after acquiring an additional 1,992 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in AngioDynamics in the fourth quarter worth $27,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in AngioDynamics by 5.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock worth $569,000 after purchasing an additional 2,263 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 6.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ANGO. Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Canaccord Genuity Group boosted their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. HC Wainwright increased their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $15.77 on Tuesday. The company has a 50-day moving average price of $14.03 and a 200-day moving average price of $12.10. The stock has a market capitalization of $651.81 million, a P/E ratio of -18.13 and a beta of 0.33. AngioDynamics, Inc. has a 1 year low of $9.39 and a 1 year high of $16.29.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities research analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.